13 June 2005 | News
Cherian Philip to head US ABLE chapter
The Association of Biotechnology Led Enterprises (ABLE) is opening its US
Chapter with Cherian Philip, chairman and managing director of Sartorius India
Pvt Ltd, Bangalore as honorary director. This was decided at its executive
council meeting held on April 25, 2005. Cherian Philip has held various
positions in the group and has built Sartorius from a single person operation to
an organization with over 300 employees currently.
ABLE's participation in the forthcoming BIO 2005 in Philadelphia from June
19-21, 2005 provides a timely launch for the US Chapter and will be an effective
platform to promote the Indian biotech industry in the US.
Dr Kiran Mazumdar Shaw, president, ABLE said, "The launch of ABLE's US
chapter is a significant milestone as India's biotechnology success needs to
be showcased in the United States. India provides a tremendous opportunity for
bio-partnering and several biotech companies in India have already forged
alliances with companies in the United States. We are certain that under the
leadership of Cherian Philip, the ABLE US chapter will be a tremendous
success."
GSK launches 'Koi Hai' program
GlaxoSmithKline (GSK) Vaccines has launched 'Koi Hai', an education program
on Hepatitis A. The program is aimed at creating awareness and educating the
public on the disease. Koi Hai program entails social interventions at the
workplace, in schools and in clinics that reach out to the various segments of
audiences. A key project is the workplace intervention program that has been
initiated in people intensive sectors for e.g. public sector units (PSUs), BPOs,
IT companies and paramilitary forces. A large-scale mass media campaign would be
prominent across the main centers in India with a film issued in public
interest. This film will be aired on various television channels.
Dr Sanjoy K Datta, medical director, GSK Vaccines, said, "Hepatitis A is a
highly infectious disease that can be prevented. Our research has proven that
awareness levels are quite low and that people are unaware of the types of
hepatitis infections, its symptoms, sources of infection and prevention methods.
This emphasizes the need for an educational campaign on hepatitis A that would
equip people to protect themselves against the possible threat of the
disease."
VH group to launch vaccines for cold, arthritis by 2007
Pune-based Venkateshwara Hatcheries (VH) group leading poultry vaccine
manufacturer, is working on three major vaccines for ailments that afflict a
majority of the common populace and expected to be released in 2007.
Common cold and cough, arthritis and pneumonia are some of the vaccines that
will hit the market in the next 18-19 months.
"We are in the final stages of the development of the vaccines and had
applied for an Indian patent. We have already obtained the US patent for these
vaccines and are presently working on the mode of dispensing the vaccines oral
or injections, " said OP Singh, CEO, Venkateshwara Hatcheries Pvt Ltd.
The objective is to provide affordable healthcare products for the masses.
Around 40 per cent of these vaccines are meant for the export market, informed
Singh. He further informed that BV Biologicals - the new entity of the VH group
set up at the Hinjewadi Biotech Park was nearing completion.
Singh said that the company is investing Rs 60 crore in the first two years and
another Rs 120 crore in the following two years. The company entered into a
tie-up with a US-based company for biodiagnostics and biogeneric products. The
aim is to bring in certain new molecules for diseases such as cancer. The
company is also investing in new vaccines and biotherapeutics for child and
adult immunization. There are plans to enter the protein drug sector as well.
Panacea Biotec posts net Rs 7.36 crore in Q4
Panacea Biotec has posted a net profit of Rs 7.36 crore for the fourth
quarter ended March 31, 2005, against Rs 0.44 crore in the same quarter the
previous year. Operating profit has increased by 42 per cent to touch Rs 14.93
crore (Rs 10.52 crore).
Panacea Biotec has achieved record turnover of Rs 335.76 crore (Rs 272.15 crore)
for the 2004-05 fiscal, a growth of 23 per cent, stated a company release.
Operating profit during the period was Rs 72.13 crore (Rs 42.43 crore). The
company recorded a net profit of Rs 30.06 crore (Rs 16.45 crore), up by 83 per
cent.
Strides Arcolab to acquire 60 percent stake in Biopharma
Strides Arcolab Ltd, a Bangalore-based pharma company, announced that its
Board of Directors approved the proposal for acquisition of up to 60 percent
stake in Biopharma, a Venezuelean pharmaceutical and marketing company. The
proposed acquisition would be at a cost not exceeding $1.00 million and would be
subject to due diligence. Post due diligence, the investment would be made by
Strides through Strides Latina SA, Uruguay the investment vehicle of the company
for its Latin American operations.
CCMB to have LACONES by July
A new Laboratory for the Conservation of Endangered Animal Species (LACONES)
will be opened in July at the Centre for Cellular and Molecular Biology (CCMB),
Hyderabad. The Laboratory will help in the preservation of endangered species
including the tiger.
Announcing this, Kapil Sibal, minister for science and technology and ocean
development said that preserving the tiger is actually persevering the human
species. He said that two different methods would be adopted for preserving the
genetic diversity of the tiger population in the country.
The first plan of action involves collection of the tigers' scat samples for
DNA finger printing, which will give an accurate picture of the number of tigers
in a forest area. If it is found that there is lack of genetic diversity, a
second method involving stunning the tiger and collection of sperms through
electro ejaculation will be adopted. The sperms having maximum virility will be
frozen and will be used for genetic diversity through artificial insemination.
In this process we do not need cloning, Sibal said. By July the process of
collecting the scat samples will be started by training the Forest Department
workers. It is a joint project by the Council for Scientific and Industrial
Research (CSIR) and the Department of Biotechnology. By the end of the year, we
shall have the complete picture of the tigers, said Sibal.
Nuziveedu launches Bt cotton strains
Nuziveedu Seeds Ltd, a seeds manufacturer, has launched Bt versions of its
cotton hybrid varieties - Bunny and Mallika. The Genetic Engineering Approval
Committee (GEAC) had cleared Bunny Bt and Mallika for commercial release in May.
Nuziveedu Seeds had entered into a pact with Mahyco-Monsanto for using Bt
technology in the new varieties.
The GEAC had earlier rejected extension for three Bt cotton varieties of Mahyco-Monsanto
in Andhra Pradesh. The GEAC approval for Nuziveedu Seeds is for the commercial
release of Bt varieties in Maharashtra, Gujarat, Madhya Pradesh, Karnataka,
Tamil Nadu and Andhra Pradesh.
"We have prepared about five lakh packets (each containing 450 gm) of Bt
hybrid seed for cultivation in the kharif season. Of these, 1.2-1.5 lakh packets
will be sold in Andhra Pradesh. Each packet contains 120 gm of hybrid
seed," said M Prabhakar Rao, managing director, Nuziveedu Seeds Ltd.
Mahyco's Bt versions get GEAC nod
The Genetic Engineering Approval Committee (GEAC) has given its approval to
Maharashtra Hybrid Seeds Company (Mahyco) to market its three varieties of Bt
cotton hybrids - MECH-12Bt, MECH-162Bt and MECH 184Bt - containing Cry 1 Ac Gene
for the central zone (consisting of Madhya Pradesh, Gujarat and Maharashtra) for
another two years. However, it decided to not to renew the permission for Mahyco
to market Bt cottonseeds in Andhra Pradesh.
For the other southern states of Tamil Nadu and Karnataka, the GEAC has approved
two of the Bt cotton hybrids (MECH-162Bt and MECH 184Bt). However, it has barred
commercialization of MECH 12 Bt for Tamil Nadu and Karnataka as well.
The GEAC had allowed commercialization of Bt cotton hybrids in the central and
south zones for three seasons beginning 2002. For the last two months, GEAC had
deferred its decision on renewal of Bt cotton following protests by civil
society groups including Greenpeace and Gene Campaign. It had, however,
permitted commercial marketing of the Bt cottonseeds in the north zone. The GEAC
has also permitted commercialization of Rasi's two hybrids of Bt cotton for
certain states. They include RCH 144 Bt for central zone that include
Maharashtra, Gujarat and Madhya Pradesh and RCH 20 Bt for southern zone that
include Andhra Pradesh, Karnataka and Tamil Nadu.